Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00232063
Status:
COMPLETED
Last Update Posted:
2011-11-02
First Post:
2005-10-03
Brief Title:
Long-term Study of Ciclosporin for Atopic Dermatitis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Long-term Study of Ciclosporin for Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients with severe adult atopic dermatitis the safety and efficacy of OL27-400MEPC will be assessed by repeating oral administration at a dose of 3 mgkgday 2-5 mgkgday in 2 divided doses daily for 8-12 weeks and recovery until 52 weeks after starting treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None